Despite 12 Deaths During Clinical Trials, CDC Signs Off on RSV Shots for Newborns, by Michael Nevradakis, Ph.D.

In Classical Schools, Kids Don’t Test For Weeks And The Quiet Ones Can Shine, by Joy Pullmann

Fr. John Bartunek, LC: What Is God’s Will? Part I Of II: His Indicative Will

cdc-rsv-shot-newborn-feature

Medical experts criticized the Centers for Disease Control and Prevention’s Thursday decision to recommend a “new immunization” for newborns to protect against respiratory syncytial virus, or RSV, calling the move unnecessary and not worth the known risks.

By Michael Nevradakis, Ph.D., Children’s Health Defense, 08/04/23

The Centers for Disease Control and Prevention (CDC) on Thursday recommended the first-ever monoclonal antibody marketed as a defense for all newborns against respiratory syncytial virus, or RSV.

Beyfortus, also known as nirsevimab, is produced by pharma giants Sanofi and AstraZeneca.

In a press release, the CDC referred to the drug as a “powerful tool” and a “new immunization.” According to the agency:

“ACIP [Advisory Committee on Immunization Practices] voted to include nirsevimab in the Vaccines for Children program, which provides recommended vaccines and immunizations at no cost to about half of the nation’s children. …